QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 us-stocks-likely-to-open-lower-after-fed-decision-any-pullback-in-equities-offers-an-opportunity-says-expert

U.S. stock futures rose on Thursday following the Federal Open Market Committee's decision on Wednesday calling inflation &...

 virpax-reveals-results-from-a-beagle-dog-dose-range-finding-study-all-the-dogs-in-drf-study-demonstrated-positive-tolerance-to-probudur-and-no-adverse-effects-were-noted

Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate ...

 us-stocks-likely-to-open-higher-following-a-sell-off-this-choppy-start-to-2025-isnt-abnormal-dont-panic-says-expert-highlighting-seasonal-weakness-in-the-first-quarter-after-elections

U.S. stock futures rose on Friday following Thursday's sell-off. Futures advanced except the small-cap gauge Russell 2000.

 penny-stock-virpax-pharmaceuticals-surges-on-us-army-performed-preclinical-study-for-pain-candidate

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgi...

 virpax-confirms-results-with-us-army-with-probudur-for-combat-care-study-showing-incision-pain-reduction-in-rat-model-aiming-to-reduce-opioid-need-long-duration-pain-control-demonstrated-up-to-5-days

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing no...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION